If you sat and did nothing for four weeks it's your own damn fault, you should have been diligently interviewing elsewhere. The rest of your rant has to be drug or alcohol fueled, you really don't belong in a professional atmosphere. Go start your revolution somewhere else.
Jury is not in yet on thus contract, although nucytnta ER needs promotion, and represents revenue. Thus still have the 1st indication in Xarelto, and depending on Thursday's panel review, he AF indication will be delayed possibly.
The contract could easily still start, with the 2nd and 3rd indications getting approved,must delayed according to plan.
My bet is that the contract is on is major territories, and most likely the contract will still move forward in all territories.
Nucynta ER needs to get in pharmacies, so this is a driving force to move forward with the contract. And Xarelto still has the knee/hip replacement indication against pulmonary embolism.
So the only thing that would rock this boat hard would be if the FDA removed the drug from the market entirely, even though it's 1st indic. was approved in July for the US.
I would think everybody should know by Friday after dust settles from Thursday advisory board meeting, and FDA's reaction to them, they can rule anyway they want. Just an advisory board.
FDA will make final call in about 12 hours.